CFDE Data Portal | Search CDC42EP3

	Label	Description
	CDC42EP3 Gene (Entity type)	ENSG00000163171 - CDC42 effector protein 3
	CDC42EP3 associations Collection (Entity type)	Associations for CDC42EP3_associations
	CDC42EP3 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	GSE216043 7 V 9 CISPLATIN HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE225869 1 V 0 TEMOZOLOMIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE135350 2 V 4 DEXAMETHASONE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE265788 IDH1 inhibition RNA-Directed DNA Polymerase 3 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE158632 3 V 5 OXYQUINOLINE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE168473 0 V 1 ISONIAZID HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE138789 metformin 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS

CDC42EP3

ENSG00000163171 - CDC42 effector protein 3

CDC42EP3 associations

Associations for CDC42EP3_associations

CDC42EP3 associations.tsv

A file from IDG as part of the Harmonizome project

GSE216043 7 V 9 CISPLATIN HUMAN DN

A Gene Set from LINCS

GSE225869 1 V 0 TEMOZOLOMIDE HUMAN DN

A Gene Set from LINCS

GSE135350 2 V 4 DEXAMETHASONE HUMAN UP

A Gene Set from LINCS

GSE265788 IDH1 inhibition RNA-Directed DNA Polymerase 3 v 2 human dn

A Gene Set from LINCS

GSE158632 3 V 5 OXYQUINOLINE HUMAN DN

A Gene Set from LINCS

GSE168473 0 V 1 ISONIAZID HUMAN UP

A Gene Set from LINCS

GSE138789 metformin 0 v 1 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.